Cargando…

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease

Tumor necrosis factor (TNF) α is a major proinflammatory cytokine involved in the immune response in inflammatory bowel disease (IBD). Anti-TNF drugs such as infliximab and adalimumab are used to treat IBD; however, approximately 30% of patients do not respond to treatment. Individual genetic differ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Prieto-Pérez, Rocío, Almoguera, Berta, Cabaleiro, Teresa, Hakonarson, Hakon, Abad-Santos, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4783957/ https://www.ncbi.nlm.nih.gov/pubmed/26861312 http://dx.doi.org/10.3390/ijms17020225

Ejemplares similares

Biomarkers for Optimization and Personalization of Anti-TNFs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Serum Bile Acids Profiling in Inflammatory Bowel Disease Patients Treated with Anti-TNFs
por: Roda, Giulia, et al.
Publicado: (2019)

Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
por: Roda, Giulia, et al.
Publicado: (2016)

Genetics of Psoriasis and Pharmacogenetics of Biological Drugs
por: Prieto-Pérez, Rocío, et al.
Publicado: (2013)

Use of anti-TNFs for difficult-to-treat urticaria: response to Cooke et al
por: Thomsen, Simon Francis, et al.
Publicado: (2015)

When rheumatology meets hepatology: are anti-TNFs safe in hepatitis B virus carriers?
por: Jansen, Tim L
Publicado: (2010)

PReS-FINAL-2250: Presentation of tuberculosis in patients using anti-TNFS drugs: report of 3 cases
por: Bica, BE, et al.
Publicado: (2013)

Assessing the functional consequence of loss of function variants using electronic medical record and large-scale genomics consortium efforts
por: Sleiman, Patrick, et al.
Publicado: (2014)

Approaches to optimising access to NICE-approved biologic anti-TNFs for patients with rheumatoid arthritis with moderately active disease
por: Taylor, Peter C., et al.
Publicado: (2023)

Polymorphisms Associated with Age at Onset in Patients with Moderate-to-Severe Plaque Psoriasis
por: Prieto-Pérez, Rocío, et al.
Publicado: (2015)

Genetic polymorphisms and associated susceptibility to asthma
por: March, Michael E, et al.
Publicado: (2013)

Imputation of TPMT defective alleles for the identification of patients with high-risk phenotypes
por: Almoguera, Berta, et al.
Publicado: (2014)

Certolizumab pegol has a different profile from other anti-TNFs, including golimumab, in a variety of in vitro assays
por: Fossati, G, et al.
Publicado: (2010)

Use of non-TNF biologics for the treatment of neuro-Behçet's disease: Literature review and 2 refractory cases of monoclonal anti-TNFs treated with tocilizumab
por: Karabulut, Yusuf
Publicado: (2022)

Copy number variation analysis in the context of electronic medical records and large-scale genomics consortium efforts
por: Connolly, John J., et al.
Publicado: (2014)

Genetic polymorphisms of inflammatory molecules in Tunisian inflammatory bowel diseases
por: Gorgi, Y, et al.
Publicado: (2010)

Real-world outcomes associated with switching to anti-TNFs versus other biologics in Crohn’s Disease patients: A retrospective analysis using German claims data
por: Zhuleku, Evi, et al.
Publicado: (2022)

Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
por: Ochoa, Dolores, et al.
Publicado: (2020)

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data
por: Wang, Kai, et al.
Publicado: (2010)

Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population
por: Zalizko, Polina, et al.
Publicado: (2020)

Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms.
por: Balding, Joanna, et al.
Publicado: (2004)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
por: Bek, S., et al.
Publicado: (2016)

Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease
por: Kamm, Florian, et al.
Publicado: (2018)

Dexketoprofen Pharmacokinetics is not Significantly Altered by Genetic Polymorphism
por: Mejía-Abril, Gina, et al.
Publicado: (2021)

Genetics of BAG3: A Paradigm for Developing Precision Therapies for Dilated Cardiomyopathies
por: Qu, Hui‐Qi, et al.
Publicado: (2022)

Correction: Serum anti-glycan-antibodies in relatives of patients with inflammatory bowel disease
por: Kamm, Florian, et al.
Publicado: (2018)

The history of genetics in inflammatory bowel disease
por: Ek, Weronica E., et al.
Publicado: (2014)

Genetic Predisposition and Inflammatory Bowel Disease
por: El-Tawil,
Publicado: (2013)

Genetic Polymorphisms Associated With the Pharmacokinetics, Pharmacodynamics and Adverse Effects of Olanzapine, Aripiprazole and Risperidone
por: Soria-Chacartegui, Paula, et al.
Publicado: (2021)

Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease
por: Nuij, V. J. A. A., et al.
Publicado: (2017)

Lactose Intolerance Assessed by Analysis of Genetic Polymorphism, Breath Test and Symptoms in Patients with Inflammatory Bowel Disease
por: Nardone, Olga Maria, et al.
Publicado: (2021)

Two Variants of the C-Reactive Protein Gene Are Associated with Risk of Pre-Eclampsia in an American Indian Population
por: Best, Lyle G., et al.
Publicado: (2013)

Correction: Two Variants of the C-Reactive Protein Gene Are Associated with Risk of Pre-Eclampsia in an American Indian Population
por: Best, Lyle G., et al.
Publicado: (2013)

Variability of the drug response to nonsteroidal anti-inflammatory drugs according to cyclooxygenase-2 genetic polymorphism
por: Lee, Sook Joung, et al.
Publicado: (2017)

Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease
por: Klein, Amir, et al.
Publicado: (2010)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

Anti-integrin therapy for inflammatory bowel disease
por: Park, Sung Chul, et al.
Publicado: (2018)

MDR1C3435T Polymorphism and Inflammatory Bowel Disease
por: Malik, Manzoor A.
Publicado: (2015)

Association between Polymorphisms in Antioxidant Genes and Inflammatory Bowel Disease
por: Costa Pereira, Cristiana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_jbbb84hkd1ku95kl0s6an2di0a